Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL21351973 | 0.93 | AKR1C4 (0.39) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL2249284 | 0.81 | HSD17B10 (0.43) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL8220004 | 0.79 | KDM4E (0.60) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL23854026 | 0.78 | CA1 (0.45) | HSD17B10TSHRLCKKDM4EPTPN1 | |
| SCHEMBL22717759 | 0.78 | KDM4E (0.44) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL1998749 | 0.78 | NAPRT (0.42) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL14901955 | 0.78 | HSD17B10 (0.44) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL4790109 | 0.78 | GABRP (0.56) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL31220104 | 0.78 | NAPRT (0.42) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL15814434 | 0.77 | CA12 (0.41) | HSD17B10TSHRKDM4ECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| CN-102321016-B | Synthesis method of 5-bromo-2-methyl hydroxypyridinecarboxylate | SHANDONG INST LIGHT INDUSTRY | 2013-04-10 | — | — | CN | disclosed |
| CN-102321016-A | Synthesis method of 5-bromo-2-methyl 4-hydroxypyridinecarboxylate | SHANDONG INST LIGHT INDUSTRY | 2012-01-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | AKR1C4 4167/4885AKR1C3 3736/4885AKR1C2 4123/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | AKR1C4 4167/4885AKR1C3 3736/4885AKR1C2 4123/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | AKR1C4 4528/4885AKR1C3 4235/4885AKR1C2 4428/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | AKR1C4 4528/4885AKR1C3 4235/4885AKR1C2 4428/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | AKR1C4 4528/4885AKR1C3 4235/4885AKR1C2 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.